RxDoctor Payments Data

Santo Grasso, DO

General Practice · Cedar Grove, NJNPI 1487788758

Payments from drug & device makers

$920in general payments, 2019–2025

Across 46 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$176
  • Atricure, Inc.$153
  • Lilly USA, LLC$130
  • KARL Storz Endoscopy-america$106
  • Dexcom, Inc.$89
  • Novo Nordisk$81
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$88796%
  • Education$334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$920 in reported general payments places this provider in the 80th percentile of 2,978 general practice providers in New Jersey.

See all general practice providers in New Jersey

Medicare billing

Part B allowed, 2024
$5,420
Medicare patients
31
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate16$19,237
JardianceEmpagliflozin20$17,028
TrulicityDulaglutide12$11,797
Breo ElliptaFluticasone/Vilanterol12$4,789
VascepaIcosapent Ethyl11$4,055
Diclofenac Sodium77$3,342
Lidocaine28$3,147
Humalog Kwikpen U-100Insulin Lispro12$1,906
Fenofibrate81$1,384
Atorvastatin Calcium133$1,271
Albuterol Sulfate HfaAlbuterol Sulfate58$1,209
Rosuvastatin Calcium44$1,186
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,151
Omega-3 Acid Ethyl Esters11$1,013
Colesevelam Hcl14$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$176$17,02820 claims
Lilly USA, LLCTrulicity, Olanzapine$130$11,93723 claims
GSKBreo Ellipta$14$4,78912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,978 general practice providers in New Jersey.

Other general practice in Cedar Grove

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →